Providence Medical Group CEO: US ‘5 to 10 years out’ from moving to single-payer

While major healthcare groups have dismissed the possibility of the U.S. adopting a single-payer system, Providence Medical Group CEO Doug Koekkoek, MD, believes a radical shift is coming in the next decade.

“I am thinking we are five to 10 years out before that is a reality,” he said, according to the Beaverton Valley Times. He later added: “Where we are headed right now is probably not sustainable. We will not get to a single-payer system in the current administration, maybe [not] even in the next. Things will have to get worse before they get better. We're probably going to have to see hospitals go out of business and communities not have access to good care.”

Koekkoek’s comments weren’t an endorsement of single-payer healthcare. He said post-Affordable Care Act trends in insurance plan design, like high-deductible plans, have discouraged people from getting care. But moving toward government-controlled reimbursement, he said, wouldn’t match the rising costs for services.

“If costs continue to go up and reimbursements do not, we are going to have hospitals go out of business,” he said. “In a city like Portland, maybe that will not be that devastating. But if you are in a one-hospital town in rural Oregon, it's going to be a big deal.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.